H.C. Wainwright Maintains Century Therapeutics(IPSC.US) With Buy Rating, Cuts Target Price to $9
Century Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $9
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cronos Group (CRON), Relay Therapeutics (RLAY) and Century Therapeutics (IPSC)
Buy Rating for Century Therapeutics Amidst Shift in Cell Therapy Market and Safety Concerns of Competitors
Century Therapeutics Analyst Ratings
Piper Sandler Maintains Overweight on Century Therapeutics, Raises Price Target to $12
Century Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Century Therapeutics, Maintains $11 Price Target
Buy Rating Affirmed for Century Therapeutics on Promising CNTY-101 Prospects and Strong Financial Footing
HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $11
Century Therapeutics Analyst Ratings
Buy Rating Affirmed for Century Therapeutics Amidst Strong Financial Backing and Promising Clinical Advances
Piper Sandler: Reiterates Century Therapeutics (IPSC.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $10.00 to $9.00.
Century Therapeutics Analyst Ratings
Century Therapeutics (IPSC) Receives a Buy From Piper Sandler
Analysts' Top Healthcare Picks: Mainz Biomed B.V. (MYNZ), Century Therapeutics (IPSC)
Strong Buy Rating for Century Therapeutics Amid Promising CNTY-101 Developments and Market Catalysts
Analysts Are Bullish on These Healthcare Stocks: Allakos (ALLK), Century Therapeutics (IPSC)
Century Therapeutics Analyst Ratings